Overview

A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
To assess the bioequivalence of reformulated OXY tablets (40 mg) relative to the original OxyContin® (OXY) formulation (40 mg) in the fed state.
Phase:
Phase 1
Details
Lead Sponsor:
Purdue Pharma LP
Treatments:
Oxycodone